An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Iveric Bio to Present at the Cowen 42nd Annual Health Care Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Iveric Bio (Nasdaq: ISEE) announced that CEO Glenn P. Sblendorio will participate in a fireside chat at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 11:10 a.m. ET. Investors and the public can access the live webcast on the Iveric Bio website, with an archived replay available for 30 days post-event. Iveric Bio focuses on developing innovative treatments for retinal diseases, aiming to improve patient outcomes. For more details, visit www.ivericbio.com.
Positive
None.
Negative
None.
PARSIPPANY, N.J.--(BUSINESS WIRE)--
IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer, will participate in a fireside chat at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022, at 11:10 a.m. Eastern Time.
Investors and the general public are invited to access the live webcast of the fireside chat on the Investor / Events & Presentations section of the Iveric Bio website at www.ivericbio.com. An archived replay of the on-demand presentation will be available on the Company’s website immediately following the conference and for at least 30 days thereafter.
About Iveric Bio Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retina diseases including earlier stages of age-related macular degeneration. For more information on the Company, please visit www.ivericbio.com.
Forward-looking Statements
Any statements in this press release or made during the presentation referenced herein about Iveric Bio’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including those described in the “Risk Factors” section of public filings made by Iveric Bio with the U.S. Securities and Exchange Commission. Any forward-looking statements represent Iveric Bio’s views only as of the date of this press release or the presentation, as applicable. Iveric Bio anticipates that subsequent events and developments may cause its views to change. While Iveric Bio may elect to update these forward-looking statements at some point in the future, Iveric Bio specifically disclaims any obligation to do so unless required by law.
